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Abstract 
Purpose: To study the therapeutic effect of He-Wei-Tong-Xie (HWXT) decoction on acute pancreatitis 
(AP) complicated with gastrointestinal dysfunction. 
Methods: AP patients (50) were recruited from the Teaching Hospital of Chengdu University of 
Traditional Chinese Medicine and randomly divided into treatment and control groups (25 per group). All 
patients were evaluated at baseline, and thereafter subjected to standard therapeutic protocols, 
including, fasting, gastrointestinal decompression, administration of somatostatin and omeprazole. The 
patients in the treatment group also received 100 mL of HWTX by nasal route with high enema (three 
times/day). Gastrointestinal function scores (stomach ache, abdominal distension, borborygmus and 
defecation), and hospitalization time were evaluated on days 3 and 7 of treatment.  
Results: No significant baseline differences were observed between the treatment and control groups 
with respect to etiological agents and AP syndrome scores (p > 0.05). However, after 3 and 7 days of 
treatment, all AP syndromes in treatment group showed significant improvement compared with the 
control patients (p < 0.01). There were no significant differences in hospitalization time and rate of 
recovery between the treatment and control groups (p < 0.01). 
Conclusion: HWTX treatment appears to be a safe and potentially useful approach for treating AP 
complicated with gastrointestinal dysfunction. 
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Acute pancreatitis (AP), known as a common 
critical threatening disease in clinics, is a serious 
inflammatory disorder of the pancreas [1,2]. AP 
induces local and systemic complications, 
especially gastrointestinal dysfunction which 
could result in gut-derived infection, sepsis, 
multiple organ dysfunction syndromes (MODS), 
and death [2-4]. Although diagnostic technology 
for AP has improved appreciably over the years, 
effective treatment drugs with low side-effects 
are still lacking [5,6].  
 
It is well known that traditional Chinese medicine 
(TCM) has been used to treat various diseases 
for thousands years in China, and the curative 
effects of most of these TCM formulas have been 
demonstrated in modern pharmacological studies 
[7-9]. In addition, increasing investigations have 
indicated that TCM formulas offer feasible 
approaches for treating AP due to their promising 
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effects on inflammatory and pain disorders, 
abdominal distension and constipation [8,10-12].  
 
He-Wei-Tong-Xie (HWTX) decoction is an 
empirical TCM formula composed of Codonopsis 
pilosula, Poriacocos, Atractylodes macrocephala, 
Citrus reticulata, Pinellia ternate, Rheum 
palmatum, Citrus aurantium, Magnolia officinalis, 
Euphorbia kansui, Glycyrrhiza uralensis and 
Glauber salt (Table 1). It has been widely used in 
our hospital for treating acute pancreatitis 
complicated with gastrointestinal dysfunction. 
However, there have been no clinical or 
experimental studies on HWTX. 
 
In the present study, we investigated the 
therapeutic effect of HWTX decoction on AP 
complicated with gastrointestinal dysfunction in 
patients from the Teaching Hospital of Chengdu 






The subjects were selected from patients 
admitted for treatments from June1, 2013 to 
December 30, 2014 in the Department of 
Emergency at The Affiliated Hospital of Chengdu 
University of Traditional Chinese Medicine 
(Chengdu, China). Male and female patients 
between the ages of 18 and 70 years were 
enrolled if they had definite diagnosis of AP. The 
diagnostic criteria were according to the 
Guidelines for the diagnosis and treatment of 
acute pancreatitis in China. These were (1) 
constant upper abdominal pain radiating to the 
back; (2) very high plasma levels of amylase and 
lipase (3 times the normal values) and (3) typical 
AP characteristic image changes by CT/MRI or 
abdomen ultrasound. A definite diagnosis was 
indicated by detection of any two of these 
criteria. All patients were required to read and 
sign informed consent forms voluntarily before 
enrollment. The study protocols were approved 
by the Ethics Committee of the affiliated hospital 
of Chengdu University of Traditional Chinese 
Medicine (no. 2013KL-035) (Chengdu, China). 
 
Preparation of He-Wei-Tong-Xie decoction 
 
HWTX is usually prepared by water decoction. 
Thus, the components of HWTX (Table 1) were 
decocted by auto drug decocting machine (North 
Pharmaceutical Equipment Manufacturing Co., 
Weifang, China) with 1500mL of water after 
soaking for 30 min. Extraction was done three 
times on the same sample. The extracts were 
pooled and filtered, and the clear supernatant 
was subsequently concentrated to 600 mL by 
using a rotary evaporator.  
 
Study design  
 
A total of 50 patients were divided randomly into 
treatment group and control group, each 
consisting of 25 patients. All patients were 
evaluated at baseline. Thereafter patients in both 
groups were treated with standard therapeutic 
protocols according to the Guidelines for the 
diagnosis and treatment of acute pancreatitis in 
China [13]. These included guardianship care, 
fasting, gastrointestinal decompression, and 
administration of somatostatin and omeprazole. 
Patients with biliary pancreatitis were given 
antibiotics and intravenous infusion. In addition to 
the standard treatments, the treatment group 
patients were administered 100 mL of HWTX by 
nasal feeding (three times/day), along with high 




Gastrointestinal function (stomachache scores, 
abdominal distension scores, borborygmus 
scores and defecation scores); hospitalization 
time, rate of disappearance of symptoms, and 
safety were evaluated at 3 and 7 days during 
treatment. 
 
         Table 1: Composition of HWTX 
 
Plant Family Part of plant Weight 
Codonopsis pilosula Campanulaceae Root 25 g 
Poriacocos Polypores Sclerotium 15 g 
Atractylodes macrocephala Asteraceae Rhizoma 12 g 
Citrus reticulate Rutaceae Pericarp 10 g 
Pinellia ternate Araceae Tuber 8 g 
Rheum palmatum Polygonaceae Root & Rhizoma 10 g 
Citrus aurantium Rutaceae Fruit 10 g 
Magnolia officinalis Magnoliaceae Cortex 10 g 
Euphorbia kansui Euphorbiaceae Tuber 0.5 g 
Glycyrrhiza uralensis Leguminosae Root 10 g 
Glauber salt - - 10 g 
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The quantitative criteria for AP symptoms in our 
present investigation (Table 2) were drawn in line 
with previous reports [3,13,14]. In addition, 
gastrointestinal function recovery criteria were 
graded as: (1) clinical control: total scores 
decreasing ≥ 95 %; (2) markedly effective: total 
scores decreasing ≥ 70 %; (3) effective: total 
scores decreasing ≥ 30 %; (4) ineffective: total 
scores decreasing < 30 %; (5) or aggravated: 




Adverse reactions were recorded during the 
investigation. Body temperature, heart rate, 
respiratory rate and blood pressure were 
monitored and routine hemogram, urinalysis, and 
liver and renal function tests were performed. 
The onset time, severity, frequency, duration, 
counter-measures and consequences of adverse 




Data are expressed as mean ± SD, and were 
analyzed using SPSS software (SPSS for 
windows 21.0, SPSS Inc, USA. Measurement 
data were analyzed by two-tailed t- test, while 
enumeration data were analyzed by Chi-square 
test. Grade comparison was by rank sum test. 





Baseline demographics and disease 
characteristics  
 
The baseline characteristics observed patients 
(age, breathing, body temperature and blood 
pressure) are shown in Table 3 while other 
baseline characteristics (white blood cell, WBC), 
neutrophil granulocyte, N), C reactive protein, 
CRP) and amylase are given in Table4. As can 
be seen from the Table, no statistically significant 
differences were observed between the 
treatment group and control group at baseline (p 
> 0.05). 
 
AP scores  
 
A similar result was obtained for AP scores 
(Table 5). Compared with patients in control 
group, no difference was seen in patients of 
treatment group in stomach ache, abdominal 
distension, borborygmus, and failure of stool and 
gas pass (p > 0.05). 
 
Stomachache, abdominal distension, 
borborygmus and defecation scores 
 
After 3 and 7 days of treatment, we compared 
stomach ache, abdominal distension, 
borborygmus and defecation scores between the 
two groups. As can be seen from Tables 6 - 8, 
patients in treatment group showed significant 
improvement in all the syndromes of AP 
compared with the control patients (p < 0.01). 
 
Disappearance of AP symptoms, 
hospitalization time and adverse reactions 
after treatment 
 
Results for comparison of rate of disappearance 
of AP symptoms, hospitalization time and 
adverse reactions after treatment are shown on 
Tables 9 - 12. No significant differences were 
observed between the treatment and control 
groups with respect to these parameters (p > 
0.05). 
 
      Table 2: Quantitative criteria for symptoms of AP 
 




Occasional request for 
analgesia; VAS: 4-6 













1-2/min No  




Failure of stool, 
and defecation 
after enema. 
Failure of stool, and 
intestinal flatulence    
       VAS: Visual Analogue Scale/Score 
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         Table 3: Baseline demographics and disease characteristics 
 
Variable Treatment (n=25) Control (n=25) p -value 
Age               
Mean 49.72 ± 13.67 45.32 ± 12.74 0.2440 
Min-Max 23.00 - 75.00 25.00 - 71.00  
Med 47.00 43.00  
Q1-Q3 40.00 - 59.50 35.50 - 54.50  
Breathing    
Mean ±_SD 26.28 ± 2.85 25.16 ± 3.26 0.2023 
Min-Max  22.00 - 34.00 20.00 - 34.00  
Med  26.00 26.00  
Q1-Q3   24.00 - 28.00 22.00 - 26.50  
Body temperature    
Mean ±_SD 37.24 ± 0.84 37.32 ± 1.01 0.7390 
Min-Max  36.00 - 38.30 36.00 - 39.20  
Med  37.30 37.30  
Q1-Q3   36.50 - 38.15 36.50 - 38.25  
Heart rate    
Mean ±_SD 96.40 ± 15.93 96.60 ± 14.55 0.9632 
Min-Max  45.00 - 132.00 62.00 - 135.00  
Med  98.00 98.00  
Q1-Q3   89.00 - 102.00 88.50 - 102.50  
Systolic pressure    
Mean ± SD 127.56 ± 15.56 123.24 ± 17.25 0.3572 
Min-Max  101.00 - 170.00 98.00 - 168.00  
Med  123.00 122.00  
Q1-Q3   119.50 - 136.00 109.50 - 137.00  
Diastolic pressure    
Mean ± SD 76.76 ± 12.64 77.64 ± 10.64 0.7912 
Min-Max  48.00 - 111.00 60.00 - 107.00  
Med  73.00 76.00  
Q1-Q3   69.00 - 82.50 70.50 - 85.50  
 
       Table 4: Baseline disease characteristics 
 
 Treatment (n=25) Control (n=25) p value 
White blood cell    
Normal 9 (36.00%) 8 (32.00%) 0.7653 
Abnormal 16 (64.00%) 17 (68.00%)  
Neutrophils    
Normal 1 (4.00%) 3 (12.00%) 0.6092 
Abnormal 24 (96.00%) 22 (88.00%)  
C reactive protein    
Normal 19 (76.00%) 14(56.00%) 0.1355 
Abnormal 6 (24.00%) 11 (44.00%)  
Amylase    
Normal 2 (8.00%) 3 (12.00%) 1.0000 
Abnormal 23 (92.00%) 22 (88.00%)  
 
        Table 5: AP scores of patients before treatment 
 
Variable Score Treatment (n=25) Control (n=25) P-value 
Stomachache 4.00 10 (40 %) 10 (40 %) 1.0000 6.00 15 (60 %) 15 (60 %) 
Abdominal distension 
2.00 2 (8 %) 3 (12 %) 
0.4189 4.00 15 (60 %) 10 (40 %) 
6.00 8 (32 %) 12 (48 %) 
Borborygmus 2.00 8 (32 %) 10 (40 %) 0.5597 4.00 17 (68 %) 15 (60 %) 
Failure of stool and 
intestinal flatulence 
0.00 0 (0 %) 2 (8 %) 
0.9545 2.00 10 (40 %) 7 (28 %) 
4.00 15 (60 %) 16 (64 %) 
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Table 6: Stomach ache scores of treatment and control groups 
 
Variable Score Treatment (n=25) Control (n=25) Z P value 
Before Treatment 4.00 10(40.00%) 10(40.00%) 0.000 1.0000 6.00 15(60.00%) 15 (60.00%) 
Three days’ treatment 
0  2(8 %) 0(0 %) 
-3.024 0.0025 2.00 11(44 %) 4(16 %) 4.00 11(44 %) 15(60 %) 
6.00 1(4 %) 6(24 %) 
Seven days’ treatment 
0  4(16 %) 0(0 %) 
-3.032 0.0024 2.00 19(76 %) 15(60 %) 4.00 1(4 %) 6(24 %) 
6.00 1(4 %) 4(16 %) 
Intra-group comparison  Z -4.396 -3.640   P value 0.000 0.000   
 
Table 7: Abdominal distension scores of treatment and control groups 
 
Variable Score Treatment (n=25) Control (n=25) Z P-value 
Before treatment 2.00 2(8 %) 3(12 %) -0.808 0.4189 
 4.00 15(60 %) 10(40 %)   
 6.00 8(32 %) 12(48 %)   
Three days’ treatment 2.00 19(76 %) 8(32 %) -3.369 0.0011 
 4.00 6(24 %) 13(52 %)   
 6.00 0(0 %) 4(16 %)   
Seven days’ treatment 0 10(40 %) 2(8 %) -2.678 0.0074 
 2.00 11(44 %) 14(56 %)   
 4.00 4(16 %) 6(2 %)   
 6.00 0(0 %) 3(12 %)   
Intra-group comparison Z -4.396 -3.739   p value 0.000 0.000   
 
Table 8: Borborygmus scores of treatment and control groups 
 
 Scores Treatment (n=25) Control (n=25) Z P-value 
Before Treatment 
 
2.00 8(32 %) 10(40 %) -0.583 0.5597 
4.00 17(68 %) 15(60 %)   
 
Three days’ treatment 
 
0  6(24 %) 0(0 %) -3.159 0.0016 
2.00 16(64 %) 14(56 %)   
4.00 3(12 %) 11(44 %)   
 
Seven days’ treatment 
 
0  10(40 %) 5(20 %) -2.367 0.0179 
2.00 15(60 %) 14(56 %)   
4.00 0(0 %) 6(24 %)   
Intra-group comparison Z -4.072 -3.276   P value 0.000 0.001   
 
Table 9: Defecation scores of treatment and control groups 
 
Variable Scores Treatment (n=25) Control (n=25) Z P-value 
Before Treatment 
0  0(0 %) 2(8 %) -0.057 0.9545 
2.00 10(40 %) 7(28 %)   
4.00 15(60 %) 16(64 %)   
Three days’ treatment 
 
0  6(24 %) 1(4 %) -2.300 0.0215 
2.00 18(72 %) 20(80 %)   
4.00 1(4 %) 4(16 %)   
Seven days’ treatment 
0  16(64 %) 13(52 %) -0.902 0.3668 
2.00 8(32 %) 10(40 %)   
4.00 1(4 %) 2(8 %)   
Intra-group comparison Z -4.388 -3.697   P value 0.000 0.000   
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Table 10: Rate of disappearance of AP symptoms 
 
Variable Result Treatment (n=25) Control (n=25) χ2 P-value 
Stoma chache  Disappeared 4(16 %) 0(0 %) 4.348 0.1099 Existed 21(84 %) 25(100 %)   
Abdominal 
distension 
Disappeared 10(40 %) 2(8 %) 7.018 0.0181 
Existed 15(60 %) 23(92 %)   
Borborygmus Disappeared 10(40 %) 5(20 %) 2.381 0.1228 Existed 15(60 %) 20(80 %)   
Failure of stool 
and gas pass 
Disappeared 16(64 %) 12(52 %) 0.689 0.4064 
Existed 9(36.00%) 11(47.83%)   
 
       Table 11: Hospitalization time of treatment and control groups 
 
Variable Treatment (n=24) Control (n=21) p value 
Full analysis set    
Mean_SD 12.46±5.85 18.10±4.96 0.0000 
Min-Max 6.00 - 36.00 10.00 - 31.00  
Med 11.50 18.00  
Q1-Q3 9.00 - 13.75 15.50 - 20.00  
Per protocol set    
Mean_SD 12.46±5.85 18.10±4.96 0.0000 
Min-Max 6.00 - 36.00 10.00 - 31.00  
Med 11.50 18.00  
Q1-Q3 9.00 - 13.75 15.50 - 20.00  
 
 
Table 12: Adverse reactions of treatment and control 
groups 
 
Variable Adverse reactions 
Rate 
% P-value 




To the best of our knowledge, the present clinical 
report is the first experimental evidence 
regarding the therapeutic effects of HWTX 
decoction on AP complicated with 
gastrointestinal dysfunction. Interestingly and 
importantly, the results show that HWTX 
administration is beneficial in the treatment of AP 
with gastrointestinal dysfunction. 
 
AP, a common acute abdominal disease, results 
from inflammatory reactions which damage the 
pancreas [3,15]. It causes acute stress, resulting 
in releases of various inflammatory cytokines and 
free radicals [3,16]. AP can easily lead to edema 
and erosion of digestive tract mucosa, resulting 
in the damage of mucosal barrier. This induces 
gut-derived infections due to translocation of gut 
bacterial endotoxin into blood [3,12]. Previous 
reports demonstrated that prognosis of AP 
patients can be greatly improved through 
recovery of gastrointestinal function and 
protection of gastrointestinal mucosal barrier. 
HWTX is derived from classical TCM formula of 
Large Chengqi Decoction and is composed of C. 
pilosula, P. cocos, A. macrocephala, C. 
reticulata, P. ternate, R. palmatum, C. aurantium, 
and M. officinalis. HWTX is an anti-bacterial 
agent which is also known to purge heat and 
flatulence from the bowels. Previous studies 
showed that the herbal components of HWTX 
possess significant beneficial effects against 
inflammatory reactions and gastrointestinal 
dysfunction [12,17,18]. In the present 
investigation, the results obtained indicate that 
HWTX in combination with standard AP 
treatment significantly improved AP syndromes 
when compared with control patients. The results 
also reveal that HWTX treatment is safe, with 
minimal side-effects. 
 
Limitation of the study 
 
In this work, the number of patients enrolled in 
the study is small, and therefore, a much higher 
number of patients would be required in future 





The findings of the present clinical study suggest 
that HWTX decoction is a safe and useful 
potential therapy for AP complicated with 
gastrointestinal dysfunction. However, further 
clinical studies are required confirm the findings 
obtained in this work. 
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